These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33317473)

  • 41. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
    Saab S; Brown RS
    Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study.
    Ding JN; Feng TT; Sun W; Cai XY; Zhang Y; Zhao WF
    World J Gastrointest Surg; 2022 Nov; 14(11):1260-1271. PubMed ID: 36504518
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lusutrombopag (Mulpleta®) treatment in a patient with thrombocytopenia complicated by cirrhosis prior to continuous epidural anesthesia during renal artery embolization: a case report.
    Sasaguri T; Hirakawa N; Uemura S
    JA Clin Rep; 2018 Nov; 4(1):80. PubMed ID: 32025904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Avoidance of platelet transfusion with readministration of lusutrombopag before radiofrequency ablation in hepatocellular carcinoma:a case report].
    Kotani S; Kohge N; Tsukano K; Ogawa S; Yamanouchi S; Kusunoki R; Aimi M; Miyaoka Y; Fujishiro H
    Nihon Shokakibyo Gakkai Zasshi; 2017; 114(10):1853-1859. PubMed ID: 28978885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lusutrombopag as pretreatment for liver biopsy following liver transplantation.
    Katano T; Sanada Y; Okada N; Mizuta K
    Pediatr Int; 2018 Nov; 60(11):1033-1034. PubMed ID: 30375132
    [No Abstract]   [Full Text] [Related]  

  • 46. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
    Abdela J
    Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure.
    Saab S; Bernstein D; Hassanein T; Kugelmas M; Kwo P
    J Clin Gastroenterol; 2020 Jul; 54(6):503-511. PubMed ID: 32195771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
    Yoshida H; Yamada H; Nogami W; Dohi K; Kurino-Yamada T; Sugiyama K; Takahashi K; Gahara Y; Kitaura M; Hasegawa M; Oshima I; Kuwabara K
    Exp Hematol; 2018 Mar; 59():30-39.e2. PubMed ID: 29274361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
    Kaneko T; Takano Y; Ishibashi K
    Medicine (Baltimore); 2021 Jan; 100(2):e24094. PubMed ID: 33466174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease.
    Lozano ML
    Rev Esp Enferm Dig; 2021 Feb; 113(2):136-140. PubMed ID: 33233913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis.
    Rose PD; Au M; Woodman RJ; Tee D; Chinnaratha MA
    Dig Liver Dis; 2021 Nov; 53(11):1396-1403. PubMed ID: 34373229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 53. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.
    Katsube T; Ishibashi T; Kano T; Wajima T
    Clin Pharmacokinet; 2016 Nov; 55(11):1423-1433. PubMed ID: 27209291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease.
    Shimizu R; Katsube T; Wajima T
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):489-499. PubMed ID: 33797208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombocytopenia and liver disease: pathophysiology and periprocedural management.
    Lim HI; Cuker A
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):296-302. PubMed ID: 36485111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thrombocytopenia associated with chronic liver disease.
    Afdhal N; McHutchison J; Brown R; Jacobson I; Manns M; Poordad F; Weksler B; Esteban R
    J Hepatol; 2008 Jun; 48(6):1000-7. PubMed ID: 18433919
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges.
    Huang A; Chen JF; Wu JZ; Gao Z; Shi YH; Fu XT; Zhang X; Liu WR; Gao Q; Sun HC; Shi GM; Fan J; Ding ZB; Zhou J
    J Oncol; 2022; 2022():9138195. PubMed ID: 36405248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.